Jinzhao He1,2, Shun Zhang1, Zhiwei Qiu1, Xiaowei Li1, Huihui Huang2,3, William Jin4, Yue Xu1, Guangying Shao1, Liang Wang1, Jia Meng1, Shuyuan Wang1, Xiaoqiang Geng1, Yingli Jia1, Min Li1,5, Baoxue Yang1,5, Hua A Jenny Lu6,3, Hong Zhou7,5. 1. State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, China. 2. Center for Systems Biology, Program in Membrane Biology and Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 3. Harvard Medical School, Boston, Massachusetts. 4. Division of Graduate Medical Sciences, Boston University School of Medicine, Boston, Massachusetts. 5. Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China. 6. Center for Systems Biology, Program in Membrane Biology and Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts Lu.Hua@mgh.harvard.edu zhouhong@bjmu.edu.cn. 7. State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, China Lu.Hua@mgh.harvard.edu zhouhong@bjmu.edu.cn.
Abstract
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by numerous cysts originating from renal tubules and is associated with significant tubular epithelial cell proliferation. Focal adhesion kinase (FAK) promotes tumor growth by regulating multiple proliferative pathways. METHODS: We established the forskolin (FSK)-induced three-dimensional (3D) Madin-Darby Canine Kidney cystogenesis model and 8-bromoadenosine-3`,5`-cyclic monophosphate-stimulated cyst formation in ex vivo embryonic kidney culture. Cultured human renal cyst-lining cells (OX-161) and normal tubular epithelial cells were treated with FAK inhibitors or transfected with green fluorescent protein-tagged FAK mutant plasmids for proliferation study. Furthermore, we examined the role of FAK in two transgenic ADPKD animal models, the kidney-specific Pkd1 knockout and the collecting duct-specific Pkd1 knockout mouse models. RESULTS: FAK activity was significantly elevated in OX-161 cells and in two ADPKD mouse models. Inhibiting FAK activity reduced cell proliferation in OX-161 cells and prevented cyst growth in ex vivo and 3D cyst models. In tissue-specific Pkd1 knockout mouse models, FAK inhibitors retarded cyst development and mitigated renal function decline. Mechanically, FSK stimulated FAK activation in tubular epithelial cells, which was blocked by a protein kinase A (PKA) inhibitor. Inhibition of FAK activation by inhibitors or transfected cells with mutant FAK constructs interrupted FSK-mediated Src activation and upregulation of ERK and mTOR pathways. CONCLUSIONS: Our study demonstrates the critical involvement of FAK in renal cyst development, suggests that FAK is a potential therapeutic target in treating patients with ADPKD, and highlights the role of FAK in cAMP-PKA-regulated proliferation.
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by numerous cysts originating from renal tubules and is associated with significant tubular epithelial cell proliferation. Focal adhesion kinase (FAK) promotes tumor growth by regulating multiple proliferative pathways. METHODS: We established the forskolin (FSK)-induced three-dimensional (3D) Madin-Darby Canine Kidney cystogenesis model and 8-bromoadenosine-3`,5`-cyclic monophosphate-stimulated cyst formation in ex vivo embryonic kidney culture. Cultured human renal cyst-lining cells (OX-161) and normal tubular epithelial cells were treated with FAK inhibitors or transfected with green fluorescent protein-tagged FAK mutant plasmids for proliferation study. Furthermore, we examined the role of FAK in two transgenic ADPKD animal models, the kidney-specific Pkd1 knockout and the collecting duct-specific Pkd1 knockout mouse models. RESULTS: FAK activity was significantly elevated in OX-161 cells and in two ADPKD mouse models. Inhibiting FAK activity reduced cell proliferation in OX-161 cells and prevented cyst growth in ex vivo and 3D cyst models. In tissue-specific Pkd1 knockout mouse models, FAK inhibitors retarded cyst development and mitigated renal function decline. Mechanically, FSK stimulated FAK activation in tubular epithelial cells, which was blocked by a protein kinase A (PKA) inhibitor. Inhibition of FAK activation by inhibitors or transfected cells with mutant FAK constructs interrupted FSK-mediated Src activation and upregulation of ERK and mTOR pathways. CONCLUSIONS: Our study demonstrates the critical involvement of FAK in renal cyst development, suggests that FAK is a potential therapeutic target in treating patients with ADPKD, and highlights the role of FAK in cAMP-PKA-regulated proliferation.
Authors: Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis Journal: Nat Rev Nephrol Date: 2015-04-14 Impact factor: 28.314
Authors: Huihui Huang; William W Jin; Ming Huang; Heyu Ji; Diane E Capen; Yin Xia; Junying Yuan; Teodor G Păunescu; Hua A Jenny Lu Journal: J Am Soc Nephrol Date: 2020-07-08 Impact factor: 10.121
Authors: David E Gerber; D Ross Camidge; Daniel Morgensztern; Jeremey Cetnar; Ronan J Kelly; Suresh S Ramalingam; David R Spigel; Woondong Jeong; Pier P Scaglioni; Song Zhang; Marilyn Li; David T Weaver; Louis Vaikus; Mitchell Keegan; Joanna C Horobin; Timothy F Burns Journal: Lung Cancer Date: 2019-11-04 Impact factor: 5.705
Authors: Edmund C Lee; Tania Valencia; Charles Allerson; Annelie Schairer; Andrea Flaten; Matanel Yheskel; Kara Kersjes; Jian Li; Sole Gatto; Mandeep Takhar; Steven Lockton; Adam Pavlicek; Michael Kim; Tiffany Chu; Randy Soriano; Scott Davis; John R Androsavich; Salma Sarwary; Tate Owen; Julia Kaplan; Kai Liu; Graham Jang; Steven Neben; Philip Bentley; Timothy Wright; Vishal Patel Journal: Nat Commun Date: 2019-09-12 Impact factor: 14.919